Novartis has agreed to pay up to $7.8 billion in a licensing deal with China-based Abogen Biosciences for global rights to an early-stage experimental autoimmune disease treatment and other RNA platform assets.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0